Mirtazapine in Comorbid Major Depression and Alcohol Use Disorder: A Long-Term Follow-Up Study.

Autor:	Cornelius JR; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA., Douaihy AB; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA., Clark DB; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA., Daley DC; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA., Chung TA; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA., Wesesky MA; University of Pittsburgh Medical Center, Pittsburgh, PA., Wood DS; University of Pittsburgh Medical Center, Pittsburgh, PA., Salloum I; University of Miami, Miami, FL.
Jazyk:	angličtina
Zdroj:	Journal of addictive behaviors, therapy & rehabilitation [J Addict Behav Ther Rehabil] 2013 Aug 24; Vol. 3 (1).
DOI:	10.4172/2324-9005.1000113
Abstrakt:	Background/objective: To date, pharmacotherapy trials of depressed alcoholics (MDD/AUD) have focused on SSRI medications, with disappointing results, so effective treatments for that comorbid population are lacking. Mirtazapine is an FDA-approved medication for treating MDD with a unique pharmacological profile whose efficacy may exceed that of SSRIs. Results from our recent open label study suggest robust acute phase efficacy for mirtazapine for decreasing both the depression and the drinking of that population. However, to date, no studies have evaluated the longer-term efficacy of mirtazapine in that population. We now report findings from a first long-term (two-year) naturalistic follow-up evaluation involving subjects from the acute phase trial. We hypothesized that the improvements would persist at follow-up. Methods: An eight-week open label study of mirtazapine and motivation therapy was conducted involving persons 18 to 55 years of age with DSM-IV diagnoses of comorbid MDD/AD. Two years after entry into the acute phase study, a long-term evaluation was conducted using the same instruments that had been used at baseline to assess whether the improvements seen during the acute phase trial had persisted. Results: Ten of the twelve patients who entered the acute phase study participated in the follow-up study. The large magnitude improvements (p<.01) in depressive symptoms (BDI), drinking (TLFB), and sleep disturbance (HDRS) persisted at the follow-up evaluation. Two of the subjects demonstrated MDD on structured interview at follow-up, while all ten had demonstrated MDD at baseline. Six of the ten used antidepressants during the follow-up period. At baseline, three were employed, while at follow-up seven were employed. Conclusions: These findings suggest long-term efficacy for mirtazapine for decreasing the drinking and depression of depressed alcoholics. Double-blind, placebo-controlled studies are warranted to clarify the efficacy of mirtazapine in depressed alcoholics.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu